To date, Biovista has profiled and screened 6 drugs with significant potential in Pancreatic Cancer. We are also exploring cross-over drugs in other tumors and will be highlighting those as we validate the results. We are in the process of filing for novel use patents for these drugs.

These drugs can be used either singly or in combination with other drugs, and we believe have significant promise in Pancreatic Cancer.

To find out more about our program in oncology please contact us.